DNA methylation inhibitors have become the mainstay for treatment of certain
haematological malignancies. In addition to their abilities to reactivate genes, including …

Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA
hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA …

DNA methylation, a key epigenetic driver of transcriptional silencing, is universally
dysregulated in cancer. Reversal of DNA methylation by hypomethylating agents, such as …

Cancer therapies that target epigenetic repressors can mediate their effects by activating
retroelements within the human genome. Retroelement transcripts can form double …

Epigenetic dysregulation is a common feature of most cancers, often occurring directly
through alteration of epigenetic machinery. Over the last several years, a new generation of …

Next-generation sequencing has revealed that more than 50% of human cancers harbour
mutations in enzymes that are involved in chromatin organization. Tumour cells not only are …

DNA-demethylating agents have shown clinical anti-tumor efficacy via an unknown
mechanism of action. Using a combination of experimental and bioinformatics analyses in …

Features of the cancer epigenome distinguish cancers from their respective cell of origin and
establish therapeutic vulnerabilities that can be exploited through pharmacologic inhibition …

Chromatin regulators have become attractive targets for cancer therapy, but it is unclear why
inhibition of these ubiquitous regulators should have gene-specific effects in tumor cells …

Methods for single-cell genome and transcriptome sequencing have contributed to our
understanding of cellular heterogeneity, whereas methods for single-cell epigenomics are …